Pfizer surpasses profit expectations in Q2, driven by strong Eliquis sales, reporting 77 cents per share versus 68 cents expected.

GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5…

Pfizer surpasses profit expectations in Q2, driven by strong Eliquis sales, reporting 77 cents per share versus 68 cents expected.